Erectile Dysfonction, a Sentinel of Cardiovascular Disease...

References

• Feldman H. A., Goldstein I., Hatzichristou D. G. et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol, 1994, 151: 54–61.
   Google Scholar
• Laumann E. O., Paik A., Rosen R. C. Sexual dysfunction in the United States: prevalence and predictors. JAMA, 1999, 281: 537–544.
   Google Scholar
• Braun M., Wassner G., Klotz T. et al. Epidemiology of erectile dysfunction: Results of the «Cologne male survey». Int J Impot Res, 2000, 12: 305–311.
   Google Scholar
• Galiano M., Pignot G., Costa C., Vallancien G., Virag R. Dysfunction érectile et cellules endothéliales caverneuses, en presse Progrès en Urologie 2010.
   Google Scholar
• Roumeguere T., Wespes E., Carpentier Y., Hoffmann P., Schulman C. C. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol, 2003, 44: 355–359.
   Google Scholar
• Montorsi P., Montorsi F., Schulman C. Is Erectile Dysfunction the “Tip of the Iceberg” of a Systemic Vascular Disorder ? Eur Urol, 2003, 44: 352–354.
   Google Scholar
• Speel T. G., Vanlangen H., Meuleman E. J. The risk of coronary heart disease in men with erectile dysfunction. Eur Urol, 2003, 44: 366–371.
   Google Scholar
• Thompson I. M., Tangen C. M., Goodman Ph. J., Probstfield J. L., Moinpour C. M., Coltman C. A. Erectile Dysfunction and Subsequent Cardiovascular Disease JAMA, 2005, 294: 2996–3002.
   Google Scholar
• Nehra A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc, 2009, 84: 139–148.
   Google Scholar
• Sullivan M. E., Thompson C. S., Dashwood M. R., Khan M. A., Jeremy J. Y., Morgan R. J., Mikhailidis D. P. Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease ? Cardiovascular Research, 1999, 43: 658–665.
   Google Scholar
• Ückert S., Hedlung P., Andersson K. F., Truss M. C., Jonas U., Jonas U., Stief C. G. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol, 2006, 50: 1194–1207.
   Google Scholar
• Andrianne R., D’Orio v. Consensus on the clinical approach to erectile dysfunction in patients with cardiovascular disease. Rev Med Liege, 2000, 55: 454–458.
   Google Scholar
• Perimenis P., Athanasopoulos A., Gyftopoulos K., Barbalias G. Sildenafil test: changes in the diagnostic and therapeutic management of erectile dysfunction. Int Urol Nephrol, 2001, 33: 387–389.
   Google Scholar
• Hatzichristou D., Hatzimouratidis K., Bekas M., Apostolidis A., Tzortzis v., Yannakoyorgos K. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol, 2002, 168: 615–620.
   Google Scholar
• Saltzman E. A., Guay A. T., Jacbson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol, 2004, 172: 255–258.
   Google Scholar
• Caro J. L. L. Sexual Dysfunction in Hypertensive Patients Treated with Losartan. Am J Med Sci, 2001, 321: 336–41.
   Google Scholar
• Derby C. A., Mohr B. A., Goldstein I. et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk ? Urology, 2000, 56: 302–306.
   Google Scholar
• Sommer F., Schulze W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors World J Urol, 2005, 23: 385–392.
   Google Scholar
• Rosano G. M. C., Aversa A., Vitale C., Fabbri A., Fini M., Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol, 2005, 47: 214–220.
   Google Scholar
• Radovits T., Bömicke T., Kökény G., Arif R., Loganathan S., Kécsán K., Korkmaz S., Barnucz E., Sandner P., Karck M., Szabó G. The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. Br J Pharmacol, 2009, 156: 909–919.
   Google Scholar
• Opsomer R. J., Wese F. X., Van Cangh P. J. Long-term results with vacuum constriction device. Proceedings of the 8th World Meeting on Impotence Research, Monduzzi Editore, International Proceedings Division, Bologna, It., 1998, pp. 271–274.
   Google Scholar
• Andrianne R, Balde S, de Leval J, Kempeners P, Mormont C. La prothèse pénienne en cas d’impuissance: 12 ans d’expérience. Acta Urol Belg, 1995, 63: 89–96.
   Google Scholar
• bis. Legros J. J., Franchimont P., Palem M. FSH, LH and Testosterone blood levels in patients with psychogenic impotency. Endocrinol Experim, 1973, 7: 59–63.
   Google Scholar
• Buvat J., Bou Jaoudé G. Significance of hypogonadism in erectile dysfunction. World J Urol, 2006, 24: 657–667.
   Google Scholar
• Earle C. M., Stuckey B. G. Biochemical screening in the assessment of erectile dysfunction: what tests decide future therapy ? Urology, 2003, 62: 727–731.
   Google Scholar
• Jannini E. A., Screponi E., Carosa E. et al. Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl, 1999, 22: 385–392.
   Google Scholar
• Kim Y. C., Buvat J., Carson C. C., Gooren L. J., Jarow J., Rajfer J., Vermeulen A. Endocrine and metabolic aspects including treatment. In: Jardin A., Wagner G., Khoury S., Giuliano F., Padma-Nathan H., Rosen R. Erectile Dysfunction. Proceedings of the First International Consultation on Erectile Dysfunction, Paris, Plymbridge, Plymouth, UK, 1999, pp 205–40.
   Google Scholar
• Morales A., Johnson B., Heaton J. W., Clark A. Oral androgens in the treatment of hypogonadal impotent men. J Urol, 1994, 152: 1115–1118.
   Google Scholar
• Morales A., Johnston B., Heaton J. P. W., Lundie M. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol, 1997, 157: 849–854.
   Google Scholar
• Wylie K, Davies-South D. A study of treatment choices in men with erectile dysfunction and reduced androgen levels. J Sex and Mar Ther, 2004, 30: 107–114.
   Google Scholar
• Buvat J., Lemaire A. Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol, 1997, 158: 764–767.
   Google Scholar
• Carosa E, Martini P, Brandetti F. et al. Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol (Oxf), 2004, 61: 382–386.
   Google Scholar
• Andrianne R., Chabot C. Penile prosthesis implantation increases total testosterone level. J Sex Res, 2008, 45: 90–117.
   Google Scholar
• Jaoudé G. B., Buvat J. Déficit en Testostérone et Dysfonction Erectile Communication Société Française de Sexologie (SFS).
   Google Scholar
• Schleich F., Legros J. J. Effects of androgen substitition on lipid profile in adult and ageing hypogonadal male. Europ J Endocrinol, 2004, 151: 415–424 .
   Google Scholar
• Smeets L, Legros J. J. Cœur et androgenes. Rev Med Lg, 2004, 59: 439–434.
   Google Scholar
• Wang C., Nieschlag E., Swerdloff R., Behre H. M., Hellstrom W. J., Gooren L. J., Kaufman J. M., Legros J. J., Lunenfeld B., Morales A., Morley J. E., Schulmann C., Thompson I. M., Weidner W., Wu F. C. Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Androl, 2009, 32: 1–10.
   Google Scholar
• Caminiti G., Volterrani M., Iellamo F., Marazzi G., Massaro R., Miceli M., Mammi C., Massimo P., Fini M., Rosano G. Effect of long-acting Testosterone treatment on functionnal exercise capacity, skeletal muscle performance, insulin resistance and baroreflex sensitivity in elderly patient with congestive heart failure. J Am Coll Cardiol, 2009, 54: 919–927.
   Google Scholar
• Shabsigh R., Arver S., Channer K. S., Eardley I., Gooren L., Heufelder A., Jones H., Meryn S., Zitsmann M. The triad of erctile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract, 2008, 62: 791–798.
   Google Scholar